1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai OPM Biosciences Co., Ltd. Class A

Shanghai OPM Biosciences Co., Ltd. Class A

SSSE:688293
58.05
CNY
+1.44
(+2.54%)
0.59EPS
37.26P/E
5.93BMarket Cap
Oct 31Next Earn
Shanghai OPM Biosciences Co., Ltd. Class A
SSE:688293
(Shanghai Stock Exchange)

Recent

price

58.05

P/E

ratio

37.26

div

yld

0.00%

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.39
0.51
1.45
2.47
2.91
2.11
2.68
3.15
5.07
Revenue per Share
-0.49
-0.11
0.14
0.7
1.04
0.47
0.19
0.37
1.12
Basic EPS, GAAP
-0.63
-0.02
-0.38
0.18
-0.35
-0.17
-0.47
0.42
- -
Free Cash Flow per Basic Share
0.01
0.02
0.02
0.02
0.02
0.64
0.46
0.43
- -
Dividend per Share
1.05
0.91
5.74
6.53
19.03
18.81
18.27
18.45
22.1
Book Value per Share
1.05
0.91
5.74
6.04
18.68
18.47
17.94
18.14
17.42
Tangible Book Value per Share
86
115
86
86
101
115
111
113
124
Basic Weighted Avg Shares
34
59
125
213
294
243
297
355
631
Sales/Revenue/Turnover
-124.94
-17.15
7.72
28.51
35.29
13.67
6.04
10.65
14.02
Operating Margin (%)
5
11
15
28
34
37
46
50
- -
Depreciation Expense
-42
-12
12
60
105
54
21
42
139
Net Income, GAAP
- -
- -
- -
11.39
11.78
13.64
44.45
16.92
0.88
Effective Tax Rate (%)
-125.52
-20.96
9.35
28.4
35.8
22.23
7.08
11.75
22.05
Profit Margin (%)
17
8
330
345
1,780
1,589
1,430
1,488
1,347
Working Capital
13
19
77
74
61
61
52
42
123
LT Debt
91
78
494
562
2,185
2,158
2,095
2,098
3,143
Total Equity
- -
- -
2.74
8.88
6.9
2.38
0.93
1.92
4.88
Return on Invested Capital (%)
- -
- -
3.93
10.13
7.42
2.56
1.08
2.07
5.29
Return on Capital (%)
- -
-14.5
4.08
11.43
7.67
2.49
0.99
1.99
5.3
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
15
38
121
LT Borrowings
- -
- -
- -
LT Finance Leases
42
132
123
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
114
139
142
Market Capitalization
5,577
5,989
5,927

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,565
2,295
1,701
Cash, Cash Equivalents & STI
1,034
1,813
1,177
Accounts Receivable, Net
95
219
234
Inventories
74
179
183
Total Current Liabilities
77
1,209
354
Payables & Accruals
- -
- -
- -
ST Debt
15
38
121
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
59.66%
0.15%
Free Cash Flow
- -
-109.74%
-191.69%
Net Income, GAAP
- -
95.93%
98.07%
Sales/Revenue/Turnover
- -
26.57%
19.4%
Total Cash Common Dividend
- -
683.48%
-4.67%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
80
64
72
81
297
2025
84
94
- -
83
355
2026
182
272
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.04
0.03
-0.05
0.19
2025
0.13
0.2
- -
-0.07
0.37
2026
0.3
0.61
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.22
0.01
0.46
2025
- -
- -
- -
- -
0.43
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai OPM Biosciences Co., Ltd. is a biotechnology company that specializes in the research, development, manufacturing, and commercialization of cell culture media products and provides comprehensive contract development and manufacturing organization (CDMO) services for the global biopharmaceutical industry. Founded in 2013 and headquartered in Shanghai, China, the company serves biopharmaceutical developers, contract research organizations, and academic institutions across the Asia-Pacific region, North America, and Europe. The company operates through two core business segments: Cell Culture Media and Biologics CDMO Services. Its cell culture media portfolio consists of chemically defined, animal origin-free, and serum-free basal media and feed formulations engineered for Chinese Hamster Ovary (CHO) cell lines, human embryonic kidney 293 (HEK293) cells, hybridoma cells, insect cells, and viral packaging hosts utilized in the manufacturing of monoclonal antibodies, bispecific antibodies, recombinant proteins, viral vaccines, and cell and gene therapies; customized media formulation development and optimization; and industrial-scale dry powder and liquid media production manufactured under current Good Manufacturing Practice (cGMP) standards. Its CDMO business, supported by its subsidiary operations including SureGen Biologics, delivers integrated end-to-end development and manufacturing solutions comprising high-expression stable cell line development; upstream and downstream bioprocess development and scale-up; analytical method development, qualification, and structural characterization; formulation development; cGMP clinical trial material manufacturing for Investigational New Drug (IND) filings; commercial-scale manufacturing; and regulatory dossier preparation for global regulatory authorities such as the NMPA, US FDA, and EMA. In recent developments following its public listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange, Shanghai OPM Biosciences Co., Ltd. has expanded its production footprint through the operational scale-up of automated, large-scale media production facilities and the addition of commercial-scale single-use bioreactor capacity to support growing biologics CDMO demand. The company has also accelerated its internationalization strategy by expanding overseas operational entities, including OPM Biosciences (USA) Inc., establishing global logistics and technical support channels, forging strategic supply agreements and research collaborations with multinational biopharmaceutical firms for customized cell culture media, and launching specialized chemically defined media platforms targeted at viral vector production for advanced cell and gene therapies.